Trabectedin Versus Pazopanib within The Treatment of Advanced, Metastatic, Leiomyosarcomas in Scotland- Results of A Cost-Effectiveness Analysis Following A Matching Adjusted Indirect Comparison
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.168
https://www.valueinhealthjournal.com/article/S1098-3015(17)30502-8/fulltext
Title :
Trabectedin Versus Pazopanib within The Treatment of Advanced, Metastatic, Leiomyosarcomas in Scotland- Results of A Cost-Effectiveness Analysis Following A Matching Adjusted Indirect Comparison
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30502-8&doi=10.1016/j.jval.2017.08.168
First page :
A427
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
149